
| ID | 71387 |
| フルテキストURL | |
| 著者 |
Takeuchi, Yasuto
Department of Gastroenterology, Okayama University Hospital
Sue, Masahiko
Department of Gastroenterology, Okayama University Hospital
Miyake, Nozomi
Department of Gastroenterology, Okayama University Hospital
Adachi, Takuya
Department of Gastroenterology, Okayama University Hospital
Onishi, Hideki
Department of Gastroenterology, Okayama University Hospital
Kawanaka, Miwa
Department of Gastroenterology, Okayama University Hospital
Takaki, Akinobu
Department of Gastroenterology, Okayama University Hospital
Kaken ID
publons
researchmap
Nouso, Kazuhiro
Department of Gastroenterology, Okayama City Hospital
ORCID
Kaken ID
publons
researchmap
Kariyama, Kazuya
Department of Gastroenterology, Okayama City Hospital
Nakamura, Shinichiro
Department of Gastroenterology, Japanese Red Cross Himeji Hospital
Tanaka, Emi
Department of Gastroenterology, Japanese Red Cross Himeji Hospital
Tada, Toshifumi
Department of Gastroenterology, Kobe University Hospital
Yasunaka, Tetsuya
Department of Gastroenterology, Fukuyama City Hospital
Kuwaki, Kenji
Department of Gastroenterology, Okayama Saiseikai General Hospital
Kaken ID
Toshimori, Junichi
Department of Gastroenterology, Japanese Red Cross Okayama Hospital
Iwado, Shota
Department of Gastroenterology, Hiroshima City Hospital
Moriya, Akio
Department of Gastroenterology, Mitoyo General Hospital
Hagihara, Hiroaki
Department of Gastroenterology, Sumitomo Besshi Hospital
Takabatake, Hiroyuki
Department of Gastroenterology, Kurashiki Central Hospital
Sakata, Masahiro
Department of Gastroenterology, Fukuyama Medical Center
Otsuka, Motoyuki
Department of Gastroenterology, Okayama University Hospital
|
| 抄録 | Background
Conversion therapy, which seeks to achieve curative treatment following systemic therapy, is increasingly acknowledged in the management of unresectable hepatocellular carcinoma (HCC). However, validated criteria for predicting eligibility for conversion remain unclear. We investigated the utility of the recently proposed borderline resectable (BR) classification combined with the barcelona clinic liver cancer (BCLC) staging system to identify patients most likely to benefit from conversion following atezolizumab plus bevacizumab (ATZ/BEV) therapy. Methods In this multicenter retrospective study, 532 patients with unresectable HCC treated with ATZ/BEV were categorized using the BR classification and stratified according to the BCLC stage. We evaluated objective response rate (ORR), conversion rate, and overall survival (OS) and carried out multivariate logistic regression analysis to identify predictors of conversion. Results Conversion therapy was performed in 5.9% of patients. Among those with BCLC-C HCC, the conversion rate was significantly higher in BR1 HCC than in BR2 HCC (15.2% vs. 2.0% and p < 0.01), and BR1 status was independently associated with conversion (odds ratio 7.0). Patients with BCLC-C/BR1 staging showed the highest ORR (45.0%) and favorable OS after conversion (p = 0.015). In contrast, the BR classification had limited predictive value in patients with BCLC-B HCC. Notably, downstaging from BR1 to resectable status was more common than from BR2, suggesting higher conversion feasibility. Conclusions Integrating BR classification with BCLC staging identified BCLC-C/BR1 patients as optimal candidates for conversion therapy after ATZ/BEV treatment. These findings support incorporating anatomical and oncological criteria into systemic strategies to enable curative interventions in advanced HCC. |
| キーワード | atezolizumab plus bevacizumab
barcelona clinic liver cancer stage
borderline resectable classification
conversion therapy
hepatocellular carcinoma
|
| 発行日 | 2026-02-09
|
| 出版物タイトル |
Hepatology Research
|
| 巻 | 56巻
|
| 号 | 5号
|
| 出版者 | Wiley
|
| 開始ページ | 830
|
| 終了ページ | 839
|
| ISSN | 1386-6346
|
| 資料タイプ |
学術雑誌論文
|
| 言語 |
英語
|
| OAI-PMH Set |
岡山大学
|
| 著作権者 | © 2026 The Author(s).
|
| 論文のバージョン | publisher
|
| PubMed ID | |
| DOI | |
| CRID | |
| 関連URL | isVersionOf https://doi.org/10.1111/hepr.70138
|
| ライセンス | https://creativecommons.org/licenses/by-nc/4.0/
|
| Citation | Takeuchi, Yasuto, Masahiko Sue, Nozomi Miyake, et al. 2026. “ Borderline Resectable Classification Identifies Candidates for Conversion Therapy in Unresectable Hepatocellular Carcinoma Treated With Atezolizumab and Bevacizumab,” Hepatology Research: 56. no. 5), 830–839. https://doi.org/10.1111/hepr.70138.
|
| 助成情報 |
22H02828:
膵癌における反復配列RNAの機能解析と治療選択最適化への応用
( 独立行政法人日本学術振興会 / Japan Society for the Promotion of Science )
23fk0210092:
慢性炎症を背景とした肝発癌の機序解明と肝癌高危険群の囲い込み法の開発
( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
23fk0210133:
RNAを中心に据えたB型肝炎の病態解明と完全排除法開発
( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
23fk0310506:
B型肝炎ウイルスのゲノム活性化・複製機序解明と創薬・標的因子同定に資する研究
( 国立研究開発法人日本医療研究開発機構 / Japan Agency for Medical Research and Development )
|